Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | Director · 10% owner | May 10, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date May 10, 2024 · Filed May 14, 2024
Jointly reported with Artal International S.C.A., Wittouck Amaury, Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Advisors, L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 136,180,481 |
Reported balance
After 2024-05-10 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-05-10 · Exercise / conversion · Acquired 57,546,100 · Balance 136,180,481 F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2: These securities are directly held by Artal International S.C.A. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,516,214 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,516,214 F3: These securities are directly held by Invus Public Equities, L.P. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 35,402,689 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 35,402,689 F4: These securities are directly held by Invus, L.P. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 1,150,922 |
Reported balance
After 2024-05-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-10 · Grant · Acquired 1,150,922 · Balance 1,150,922 F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2: These securities are directly held by Artal International S.C.A. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2024-05-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-10 · Exercise / conversion · Disposed 1,150,922 · Balance 0 F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2: These securities are directly held by Artal International S.C.A. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.
F2: These securities are directly held by Artal International S.C.A.
F3: These securities are directly held by Invus Public Equities, L.P.
F4: These securities are directly held by Invus, L.P.
F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.
F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Buffalo Pet Products, Inc.
Report date April 24, 2018 · Filed April 24, 2018
Jointly reported with Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Minne Pascal, Invus Advisors, L.L.C.
Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-04-24 · Disposition to issuer · Disposed 87,460,875 · Balance 0 F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. F3: These securities are directly held by Invus, L.P. F4: Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend ("Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.
F3: These securities are directly held by Invus, L.P.
F4: Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend ("Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.
F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2024 Filed May 14, 2024 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionSeries A Convertible Preferred Stock · Derivative | 1,150,922 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059789 · ownership.xml · derivative · entry 5 Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Wittouck Amaury · CIK 0001841311 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 57,546,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F1 · kind: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F1 · derivative.exercise_date: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F1 · derivative.expiration_date: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2 · ownership.nature: These securities are directly held by Artal International S.C.A. F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 10, 2024 Filed May 14, 2024 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantSeries A Convertible Preferred Stock · Derivative | 1,150,922 | $108.50 | $124,875,037.00 |
DisclosureSEC source: 0000950170-24-059789 · ownership.xml · derivative · entry 4 Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Wittouck Amaury · CIK 0001841311 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,150,922 Underlying: Common Stock · 57,546,100 shares Expires not disclosed F1 · derivative.exercise_price: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F1 · kind: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F1 · price: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F1 · derivative.exercise_date: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F1 · derivative.expiration_date: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2 · ownership.nature: These securities are directly held by Artal International S.C.A. F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 10, 2024 Filed May 14, 2024 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 57,546,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-059789 · ownership.xml · nonDerivative · entry 1 Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Wittouck Amaury · CIK 0001841311 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 136,180,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F1 · price: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2 · ownership.nature: These securities are directly held by Artal International S.C.A. F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 01:22 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantSeries A Convertible Preferred Stock | 1,150,922 | $108.50 | $124,875,037.00 |
DisclosureSEC source: 0000950170-24-031072 · ownership.xml · nonDerivative · entry 1 Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Wittouck Amaury · CIK 0001841311 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,150,922 F1 · kind: On March 11, 2024, Artal International S.C.A. entered into a purchase agreement (the "Purchase Agreement") with the Issuer pursuant to which Artal International S.C.A. agreed to purchase 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share (the "Purchase Price"). Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on March 13, 2024. F2 · ownership.nature: These securities are directly held by Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F3 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 05, 2023 Filed Jun 5, 2023 20:46 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 27,775,050 | $2.60 | $72,215,130.00 |
DisclosureSEC source: 0000899243-23-014464 · doc4.xml · nonDerivative · entry 1 Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Wittouck Amaury · CIK 0001841311 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 78,634,381 F1 · kind: On May 31, 2023, Artal International S.C.A. entered into a purchase agreement (the "Purchase Agreement") with the Issuer pursuant to which Artal International S.C.A. agreed to purchase 24,152,218 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), of the Issuer at a price of $2.60 per share (the "Purchase Price"). The Purchase Agreement also provided Artal International S.C.A. the right to purchase from the Issuer, on a pro rata basis, up to an additional 3,622,832 shares of Issuer Common Stock at a price per share equal to the Purchase Price. On June 1, 2023, pursuant to the 2023 Purchase Agreement, Artal International S.C.A. exercised its right to purchase an additional 3,622,832 shares of Issuer Common Stock at a price per share equal to the Purchase Price. The purchase closed on June 5, 2023. F2 · ownership.nature: These securities are directly held by Artal International S.C.A. F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:46 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 2,426,070 | $2.50 | $6,065,175.00 |
DisclosureSEC source: 0000899243-22-028108 · doc4.xml · nonDerivative · entry 1 Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Wittouck Amaury · CIK 0001841311 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 50,859,331 F1 · kind: Pursuant to a purchase agreement dated July 27, 2022, between Artal International S.C.A. and the Issuer, on August 5, 2022, Artal International S.C.A. purchased an additional 2,426,070 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock. F2 · ownership.nature: These securities are directly held by Artal International S.C.A. F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The parent company of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 20:15 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 16,173,800 | $2.50 | $40,434,500.00 |
DisclosureSEC source: 0000899243-22-027156 · doc4.xml · nonDerivative · entry 1 Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Wittouck Amaury · CIK 0001841311 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 48,433,261 F1 · kind: On July 27, 2022, Artal International S.C.A. entered into a purchase agreement with the Issuer pursuant to which Artal International S.C.A. agreed to purchase 16,173,800 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), of the Issuer at a price of $2.50 per share. The purchase closed on August 1, 2022. F2 · ownership.nature: These securities are directly held by Artal International S.C.A. F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The parent company of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 19:39 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 10,937,500 | $3.20 | $35,000,000.00 |
DisclosureSEC source: 0000899243-20-034268 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal Treasury Ltd · CIK 0001766952 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 32,259,461 F1 · kind: On December 11, 2020, Artal International S.C.A. entered into a subscription agreement with the Issuer and other parties thereto, pursuant to which Artal International S.C.A. agreed to purchase 10,937,500 shares of Class A common stock of the Issuer at a price of $3.20 per share. The purchase closed on December 16, 2020. F2 · ownership.nature: These securities are directly held by Artal International S.C.A. F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal Treasury Limited is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. and, through its Geneva branch, is the sole stockholder of Artal Treasury Limited. The managing partner of Artal International S.C.A. is Artal International Management S.A. The parent company of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. F7 · ownership.nature: Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 4. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:23 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 57,724 | $12.45 | $718,935.10 |
DisclosureSEC source: 0000899243-18-018727 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,516,214 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 27, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.40 to $12.60 per share and the shares reported as purchased on June 28, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.22 to $12.76 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:23 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 125,114 | $12.54 | $1,568,441.62 |
DisclosureSEC source: 0000899243-18-018727 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,458,490 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 27, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.40 to $12.60 per share and the shares reported as purchased on June 28, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.22 to $12.76 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 21:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 228,264 | $12.95 | $2,955,082.92 |
DisclosureSEC source: 0000899243-18-018161 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,333,376 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 22, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.14 to $13.49 per share and the shares reported as purchased on June 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.57 to $13.08 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 25,461 | $13.36 | $340,090.22 |
DisclosureSEC source: 0000899243-18-018161 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,105,112 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 22, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.14 to $13.49 per share and the shares reported as purchased on June 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.57 to $13.08 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 21, 2018 Filed Jun 21, 2018 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 51,600 | $13.27 | $684,613.32 |
DisclosureSEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,079,651 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 12,391 | $13.28 | $164,613.20 |
DisclosureSEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,028,051 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 8,982 | $13.45 | $120,818.68 |
DisclosureSEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,015,660 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 18, 2018 Filed Jun 18, 2018 22:56 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 36,584 | $13.06 | $477,937.03 |
DisclosureSEC source: 0000899243-18-017071 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,006,678 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 22:56 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 9,200 | $12.66 | $116,461.88 |
DisclosureSEC source: 0000899243-18-017071 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,970,094 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 12, 2018 Filed Jun 12, 2018 22:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 107,023 | $12.83 | $1,373,244.22 |
DisclosureSEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,960,894 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 22:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 98,626 | $12.75 | $1,257,451.91 |
DisclosureSEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,853,871 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 22:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 29,747 | $12.89 | $383,426.93 |
DisclosureSEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,755,245 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 23:37 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 57,439 | $12.93 | $742,508.21 |
DisclosureSEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,725,498 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 23:37 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 95,079 | $12.58 | $1,196,369.55 |
DisclosureSEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,668,059 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:37 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 173,121 | $12.45 | $2,156,187.43 |
DisclosureSEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,572,980 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 04, 2018 Filed Jun 4, 2018 21:31 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 121,803 | $12.24 | $1,490,576.39 |
DisclosureSEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,399,859 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:31 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,339 | $12.22 | $1,800,040.56 |
DisclosureSEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,278,056 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:31 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,339 | $11.62 | $1,712,049.71 |
DisclosureSEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,130,717 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 30, 2018 Filed May 31, 2018 00:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,339 | $10.32 | $1,521,024.70 |
DisclosureSEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,983,378 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 29, 2018 Filed May 31, 2018 00:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,339 | $9.84 | $1,450,419.85 |
DisclosureSEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,836,039 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 25, 2018 Filed May 31, 2018 00:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 138,700 | $9.62 | $1,334,973.63 |
DisclosureSEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,688,700 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| April 24, 2018 Filed Apr 24, 2018 21:03 UTC | Blue Buffalo Pet Products, Inc. BUFF · Entity 167336 | Disposition to issuerCommon Stock | 87,460,875 | $40.00 | $3,498,435,000.00 |
DisclosureSEC source: 0000899243-18-010670 · doc4.xml · nonDerivative · entry 1 Invus, L.P. · CIK 0001404570 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. F3 · ownership.direct: These securities are directly held by Invus, L.P. F4 · ownership.direct: Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend ("Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F5 · ownership.direct: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 17, 2017 Filed Nov 18, 2017 01:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 50,000 | $9.85 | $492,500.00 |
DisclosureSEC source: 0000899243-17-026881 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,550,000 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 15, 2017 Filed Nov 18, 2017 01:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 130,727 | $10.21 | $1,334,395.85 |
DisclosureSEC source: 0000899243-17-026881 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,500,000 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on November 15, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.75 to $10.49 per share. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 14, 2017 Filed Nov 15, 2017 00:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 215,133 | $9.47 | $2,037,847.34 |
DisclosureSEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,369,273 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 00:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 215,133 | $9.75 | $2,097,933.99 |
DisclosureSEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,154,140 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 10, 2017 Filed Nov 15, 2017 00:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 145,680 | $9.74 | $1,418,384.18 |
DisclosureSEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 939,007 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| September 16, 2016 Filed Sep 16, 2016 22:29 UTC | Blue Buffalo Pet Products, Inc. BUFF · Entity 167336 | SaleCommon Stock | 12,512,124 | $24.83 | $310,642,256.19 |
DisclosureSEC source: 0000899243-16-029167 · doc4.xml · nonDerivative · entry 1 Invus, L.P. · CIK 0001404570 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,460,875 F1 · price: This amount represents the $24.8273 sales price per share of common stock of the Issuer received by Invus, L.P. in connection with a secondary block trade which closed on September 16, 2016. F2 · ownership.direct: These securities are directly held by Invus, L.P. F3 · ownership.direct: Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend ("Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4 · ownership.direct: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.